Open-label extension of zasocitinib in adults with ulcerative colitis and Crohn's disease

Phase 2, open-label trial of zasocitinib in autoimmune colitis and Crohn's disease (2 arms), sponsored by Takeda. Primary endpoints: Incidence of treatment-emergent adverse events by indication, Clinically significant safety parameter changes by indication and 1 more. Planned start Aug 2025; status: authorised.